Evaluation of bioactive sphingolipids in 4-HPR-resistant leukemia cells

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Apraiz, Aintzane ^a   Idkowiak Baldys, Jolanta K ^b   Boyano, María D ^a   Pérez Yarza, Gorka ^a   Hannun, Yusuf A ^b   Asumendi, Aintzane ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN; CERAMIDE GLUCOSYLTRANSFERASE; DIHYDROCERAMIDE DESATURASE; OXYGENASE; PROPIDIUM IODIDE; SPHINGOLIPID; SPHINGOSINE KINASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; FENRETINIDE; OXIDOREDUCTASE; SAFINGOL; SPHINGOSINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CELL CYCLE ARREST; CELL LABELING; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHENOTYPE; PLASTICITY; ANALYSIS OF VARIANCE; APOPTOSIS; CELL SURVIVAL; DRUG EFFECT; LEUKEMIA; METABOLISM; TUMOR CELL CULTURE;

ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; FENRETINIDE; HUMANS; LEUKEMIA; OXIDOREDUCTASES; SPHINGOLIPIDS; SPHINGOSINE; TUMOR CELLS, CULTURED;

EID: 80355145679     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-477     Document Type: Article

References (53)

1. O'Donnell PH, Guo WX, Reynolds CP, Maurer BJ. N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes. Leukemia 2002, 16:902-910. 10.1038/sj.leu.2402485, 11986953.
2. Asumendi A, Morales MC, Alvarez A, Aréchaga J, Pérez-Yarza G. Implication of mitochondria-derived ROS and cardiolipin peroxidation in N-(4-hydroxyphenyl)retinamide-induced apoptosis. Br J Cancer 2002, 86:1951-1956. 10.1038/sj.bjc.6600356, 2375439, 12085192.
3. Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, Penson DF, Matin S, Kamat A, Pisters LL, et al. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res 2008, 14:224-229. 10.1158/1078-0432.CCR-07-0733, 18172274.
4. Decensi A, Robertson C, Guerrieri-Gonzaga A, Serrano D, Cazzaniga M, Mora S, Gulisano M, Johansson H, Galimberti V, Cassano E, et al. Randomized double-blind 2 × 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. J Clin Oncol 2009, 27:3749-3756. 10.1200/JCO.2008.19.3797, 2799048, 19597031.
5. Delia D, Aiello A, Lombardi L, Pelicci PG, Grignani F, Formelli F, Menard S, Costa A, Veronesi U. N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 1993, 53:6036-6041.
6. Appierto V, Cavadini E, Pergolizzi R, Cleris L, Lotan R, Canevari S, Formelli F. Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line. Br J Cancer 2001, 84:1528-1534. 10.1054/bjoc.2001.1826, 2363672, 11384104.
7. Prinetti A, Basso L, Appierto V, Villani MG, Valsecchi M, Loberto N, Prioni S, Chigorno V, Cavadini E, Formelli F, Sonnino S. Altered sphingolipid metabolism in N-(4-hydroxyphenyl)-retinamide-resistant A2780 human ovarian carcinoma cells. J Biol Chem 2003, 278:5574-5583. 10.1074/jbc.M207269200, 12486134.
8. Wang H, Maurer BJ, Liu YY, Wang E, Allegood JC, Kelly S, Symolon H, Liu Y, Merrill AH, Gouazé-Andersson V, et al. N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing. Mol Cancer Ther 2008, 7:2967-2976. 10.1158/1535-7163.MCT-08-0549, 18790777.
9. Mellor HR, Callaghan R. Resistance to chemotherapy in cancer: a complex and integrated cellular response. Pharmacology 2008, 81:275-300. 10.1159/000115967, 18259091.
10. Goto H, Takahashi H, Fujii H, Ikuta K, Yokota S. N-(4-Hydroxyphenyl)retinamide (4-HPR) induces leukemia cell death via generation of reactive oxygen species. Int J Hematol 2003, 78:219-225. 10.1007/BF02983798, 14604280.
11. Kadara H, Lacroix L, Lotan D, Lotan R. Induction of endoplasmic reticulum stress by the pro-apoptotic retinoid N-(4-hydroxyphenyl)retinamide via a reactive oxygen species-dependent mechanism in human head and neck cancer cells. Cancer Biol Ther 2007, 6:705-711. 10.4161/cbt.6.5.3963, 17404501.
12. Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines. J Natl Cancer Inst 1999, 91:1138-1146. 10.1093/jnci/91.13.1138, 10393722.
13. Morales MC, Pérez-Yarza G, Rementería NN, Boyano MD, Apraiz A, Gómez-Muñoz A, Pérez-Andrés E, Asumendi A. 4-HPR-mediated leukemia cell cytotoxicity is triggered by ceramide-induced mitochondrial oxidative stress and is regulated downstream by Bcl-2. Free Radic Res 2007, 41:591-601. 10.1080/10715760701218558, 17454142.
14. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008, 9:139-150. 10.1038/nrm2329, 18216770.
15. Maurer BJ, Melton L, Billups C, Cabot MC, Reynolds CP. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J Natl Cancer Inst 2000, 92:1897-1909. 10.1093/jnci/92.23.1897, 11106681.
16. Batra S, Reynolds CP, Maurer BJ. Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. Cancer Res 2004, 64:5415-5424. 10.1158/0008-5472.CAN-04-0377, 15289350.
17. Illuzzi G, Bernacchioni C, Aureli M, Prioni S, Frera G, Donati C, Valsecchi M, Chigorno V, Bruni P, Sonnino S, Prinetti A. Sphingosine kinase mediates resistance to the synthetic retinoid N-(4-hydroxyphenyl)retinamide in human ovarian cancer cells. J Biol Chem 2010, 285:18594-18602. 10.1074/jbc.M109.072801, 2881785, 20404323.
18. Gouazé-Andersson V, Yu JY, Kreitenberg AJ, Bielawska A, Giuliano AE, Cabot MC. Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells. Biochim Biophys Acta 2007, 1771:1407-1417.
19. Kraveka JM, Li L, Szulc ZM, Bielawski J, Ogretmen B, Hannun YA, Obeid LM, Bielawska A. Involvement of dihydroceramide desaturase in cell cycle progression in human neuroblastoma cells. J Biol Chem 2007, 282:16718-16728. 10.1074/jbc.M700647200, 2084375, 17283068.
20. Shikata K, Niiro H, Azuma H, Ogino K, Tachibana T. Apoptotic activities of C2-ceramide and C2-dihydroceramide homologues against HL-60 cells. Bioorg Med Chem 2003, 11:2723-2728. 10.1016/S0968-0896(03)00228-1, 12788346.
21. Signorelli P, Munoz-Olaya JM, Gagliostro V, Casas J, Ghidoni R, Fabriàs G. Dihydroceramide intracellular increase in response to resveratrol treatment mediates autophagy in gastric cancer cells. Cancer Lett 2009, 282:238-243. 10.1016/j.canlet.2009.03.020, 19394759.
22. Szulc ZM, Bielawski J, Gracz H, Gustilo M, Mayroo N, Hannun YA, Obeid LM, Bielawska A. Tailoring structure-function and targeting properties of ceramides by site-specific cationization. Bioorg Med Chem 2006, 14:7083-7104. 10.1016/j.bmc.2006.07.016, 16919460.
23. Berridge MV, Herst PM, Tan AS. Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev 2005, 11:127-152.
24. Bielawski J, Szulc ZM, Hannun YA, Bielawska A. Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods 2006, 39:82-91. 10.1016/j.ymeth.2006.05.004, 16828308.
25. Van Veldhoven PP, Bell RM. Effect of harvesting methods, growth conditions and growth phase on diacylglycerol levels in cultured human adherent cells. Biochim Biophys Acta 1988, 959:185-196.
26. Spassieva S, Bielawski J, Anelli V, Obeid LM. Combination of C(17) sphingoid base homologues and mass spectrometry analysis as a new approach to study sphingolipid metabolism. Methods Enzymol 2007, 434:233-241.
27. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004, 4:604-616. 10.1038/nrc1411, 15286740.
28. Berdyshev EV, Gorshkova IA, Usatyuk P, Zhao Y, Saatian B, Hubbard W, Natarajan V. De novo biosynthesis of dihydrosphingosine-1-phosphate by sphingosine kinase 1 in mammalian cells. Cell Signal 2006, 18:1779-1792. 10.1016/j.cellsig.2006.01.018, 16529909.
29. Tiwari M, Kumar A, Sinha RA, Shrivastava A, Balapure AK, Sharma R, Bajpai VK, Mitra K, Babu S, Godbole MM. Mechanism of 4-HPR-induced apoptosis in glioma cells: evidences suggesting role of mitochondrial-mediated pathway and endoplasmic reticulum stress. Carcinogenesis 2006, 27:2047-2058. 10.1093/carcin/bgl051, 16675469.
30. Liu YY, Han TY, Giuliano AE, Cabot MC. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J Biol Chem 1999, 274:1140-1146. 10.1074/jbc.274.2.1140, 9873062.
31. Veldman RJ, Klappe K, Hinrichs J, Hummel I, van der Schaaf G, Sietsma H, Kok JW. Altered sphingolipid metabolism in multidrug-resistant ovarian cancer cells is due to uncoupling of glycolipid biosynthesis in the Golgi apparatus. FASEB J 2002, 16:1111-1113.
32. Olshefski RS, Ladisch S. Glucosylceramide synthase inhibition enhances vincristine-induced cytotoxicity. Int J Cancer 2001, 93:131-138. 10.1002/ijc.1301, 11391632.
33. Xie P, Shen YF, Shi YP, Ge SM, Gu ZH, Wang J, Mu HJ, Zhang B, Qiao WZ, Xie KM. Overexpression of glucosylceramide synthase in associated with multidrug resistance of leukemia cells. Leuk Res 2008, 32:475-480. 10.1016/j.leukres.2007.07.006, 17709137.
34. Di Sano F, Fazi B, Citro G, Lovat PE, Cesareni G, Piacentini M. Glucosylceramide synthase and its functional interaction with RTN-1C regulate chemotherapeutic-induced apoptosis in neuroepithelioma cells. Cancer Res 2003, 63:3860-3865.
35. Lovat PE, Di Sano F, Corazzari M, Fazi B, Donnorso RP, Pearson AD, Hall AG, Redfern CP, Piacentini M. Gangliosides link the acidic sphingomyelinase-mediated induction of ceramide to 12-lipoxygenase-dependent apoptosis of neuroblastoma in response to fenretinide. J Natl Cancer Inst 2004, 96:1288-1299. 10.1093/jnci/djh254, 15339967.
36. Hait NC, Oskeritzian CA, Paugh SW, Milstien S, Spiegel S. Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim Biophys Acta 2006, 1758:2016-2026. 10.1016/j.bbamem.2006.08.007, 16996023.
37. Hannun YA, Loomis CR, Merrill AH, Bell RM. Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets. J Biol Chem 1986, 261:12604-12609.
38. Merrill AH, Nimkar S, Menaldino D, Hannun YA, Loomis C, Bell RM, Tyagi SR, Lambeth JD, Stevens VL, Hunter R. Structural requirements for long-chain (sphingoid) base inhibition of protein kinase C in vitro and for the cellular effects of these compounds. Biochemistry 1989, 28:3138-3145. 10.1021/bi00434a004, 2742830.
39. French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, Yun JK, Smith CD. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003, 63:5962-5969.
40. French KJ, Upson JJ, Keller SN, Zhuang Y, Yun JK, Smith CD. Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther 2006, 318:596-603. 10.1124/jpet.106.101345, 2660408, 16632640.
41. Villani MG, Appierto V, Cavadini E, Bettiga A, Prinetti A, Clagett-Dame M, Curley RW, Formelli F. 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines. Cancer Res 2006, 66:3238-3247. 10.1158/0008-5472.CAN-05-3362, 16540676.
42. Ponzanelli I, Giannì M, Giavazzi R, Garofalo A, Nicoletti I, Reichert U, Erba E, Rambaldi A, Terao M, Garattini E. Isolation and characterization of an acute promyelocytic leukemia cell line selectively resistant to the novel antileukemic and apoptogenic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid. Blood 2000, 95:2672-2682.
43. Holmes WF, Soprano DR, Soprano KJ. Elucidation of molecular events mediating induction of apoptosis by synthetic retinoids using a CD437-resistant ovarian carcinoma cell line. J Biol Chem 2002, 277:45408-45419. 10.1074/jbc.M204600200, 12237293.
44. Charruyer A, Jean C, Colomba A, Jaffrézou JP, Quillet-Mary A, Laurent G, Bezombes C. PKCzeta protects against UV-C-induced apoptosis by inhibiting acid sphingomyelinase-dependent ceramide production. Biochem J 2007, 405:77-83. 1925242, 17346242.
45. Lacour S, Hammann A, Grazide S, Lagadic-Gossmann D, Athias A, Sergent O, Laurent G, Gambert P, Solary E, Dimanche-Boitrel MT. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res 2004, 64:3593-3598. 10.1158/0008-5472.CAN-03-2787, 15150117.
46. Martínez R, Navarro R, Lacort M, Ruiz-Sanz JI, Ruiz-Larrea MB. Doxorubicin induces ceramide and diacylglycerol accumulation in rat hepatocytes through independent routes. Toxicol Lett 2009, 190:86-90. 10.1016/j.toxlet.2009.07.010, 19607893.
47. Pautz A, Franzen R, Dorsch S, Böddinghaus B, Briner VA, Pfeilschifter J, Huwiler A. Cross-talk between nitric oxide and superoxide determines ceramide formation and apoptosis in glomerular cells. Kidney Int 2002, 61:790-796. 10.1046/j.1523-1755.2002.00222.x, 11849427.
48. Swanton C, Marani M, Pardo O, Warne PH, Kelly G, Sahai E, Elustondo F, Chang J, Temple J, Ahmed AA, et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 2007, 11:498-512. 10.1016/j.ccr.2007.04.011, 17560332.
49. Alexandre J, Batteux F, Nicco C, Chéreau C, Laurent A, Guillevin L, Weill B, Goldwasser F. Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int J Cancer 2006, 119:41-48. 10.1002/ijc.21685, 16450384.
50. Bragado P, Armesilla A, Silva A, Porras A. Apoptosis by cisplatin requires p53 mediated p38alpha MAPK activation through ROS generation. Apoptosis 2007, 12:1733-1742. 10.1007/s10495-007-0082-8, 17505786.
51. Gouazé V, Mirault ME, Carpentier S, Salvayre R, Levade T, Andrieu-Abadie N. Glutathione peroxidase-1 overexpression prevents ceramide production and partially inhibits apoptosis in doxorubicin-treated human breast carcinoma cells. Mol Pharmacol 2001, 60:488-496.
52. Takai D, Park SH, Takada Y, Ichinose S, Kitagawa M, Akashi M. UV-irradiation induces oxidative damage to mitochondrial DNA primarily through hydrogen peroxide: analysis of 8-oxodGuo by HPLC. Free Radic Res 2006, 40:1138-1148. 10.1080/10715760600838381, 17050167.
53. Idkowiak-Baldys J, Apraiz A, Li L, Rahmaniyan M, Clarke CJ, Kraveka JM, Asumendi A, Hannun YA. Dihydroceramide desaturase activity is modulated by oxidative stress. Biochem J 2010, 427:265-274. 10.1042/BJ20091589, 3086801, 20105137.